Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Piclidenoson - Can-Fite Biopharma

Drug Profile

Piclidenoson - Can-Fite Biopharma

Alternative Names: CF 101; IB-MECA; SI 615

Latest Information Update: 02 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Can-Fite BioPharma
  • Developer Can-Fite BioPharma; Fondazione Telethon
  • Class Amides; Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Antivirals; Eye disorder therapies; Iodobenzenes; Neuroprotectants; Purine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Adenosine A3 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Plaque psoriasis
  • Phase II COVID 2019 infections
  • Preclinical Oculocerebrorenal syndrome
  • Discontinued Colorectal cancer; Dry eyes; Glaucoma; Ocular hypertension; Osteoarthritis; Rheumatoid arthritis; Solid tumours; Uveitis

Most Recent Events

  • 30 Jan 2024 Ewopharma exercises its right to expand the distribution agreement with Can-Fite Biopharma to include the indication of pancreatic cancer
  • 29 Jan 2024 Phase-III COMFORT-2 clinical trials in Plaque psoriasis (PO) prior to January 2024
  • 30 Nov 2023 Can-Fite Biopharma plans a clinical trial for oculocerebrorenal syndrome
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top